Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383508 | 0.84 | FOLH1 (0.60) | FOLH1KDM4EHPGDSMN1; SMN2PTGER1 | |
| SCHEMBL2341192 | 0.80 | HPGD (0.49) | KDM4EHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL2343079 | 0.79 | MAOB (0.59) | KDM4EHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL4308031 | 0.78 | MEN1 (0.65) | FOLH1KDM4EHPGDLMNAMEN1 | |
| SCHEMBL793724 | 0.78 | MEN1 (0.65) | KDM4EHPGDLMNASMN1; SMN2PTGER1 | |
| SCHEMBL382550 | 0.78 | FOLH1 (0.56) | FOLH1KDM4ESMN1; SMN2PTGER1MEN1 | |
| SCHEMBL5839199 | 0.78 | FOLH1 (0.56) | FOLH1KDM4ESMN1; SMN2PTGER1MCL1 | |
| SCHEMBL14660694 | 0.77 | MEN1 (0.63) | KDM4EHPGDLMNASMN1; SMN2PTGER1 | |
| Hydrochloric Acid SCHEMBL514496 | 0.77 | MEN1 (0.63) | KDM4EHPGDLMNASMN1; SMN2PTGER1 | |
| SCHEMBL4015321 | 0.77 | FOLH1 (0.55) | FOLH1KDM4ESMN1; SMN2PTGER1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| US-8816087-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-7700625-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LTD. (GB) | 2010-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | HSP90AA1, HSP90AB1, HSP90AB2P | FOLH1 3899/4885KDM4E 3949/4885HPGD 45/4885 |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, GSK3A | FOLH1 4250/4885KDM4E 3095/4885HPGD 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.